Primer: Genuine Biotech (GBL HK) - Apr 2026
Genuine Biotech is a Chinese biotechnology firm facing significant financial distress, making its third attempt at a Hong Kong IPO a critical,...
107 Views
Genuine Biotech (真实生物) Pre-IPO: Challenges Amid Restructuring
Genuine Biotech seeks to raise $100 million through Hong Kong listing with CICC as sole sponsor. Our further look suggest the company is facing...
373 Views
Will the Approval of Genuine Biotech's COVID-19 Oral Drug Change China's Zero-COVID Policy?
Due to VBP/fierce competition/weak demand, Azivudine's outlook is challenging.Until President Xi’s 3rd term appointment is confirmed,there’s no...
407 Views
ECM Weekly (24 November 2025) - CATL, Hengrui, Hongqiao, WT Micro, SBI Shinsei, NS Group, Ultragreen
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
496 Views
Pre-IPO Genuine Biotech - The Current Pipeline Hardly Supports High Valuation
Genuine's commercialization focuses on azvudine, but long-term valuation should exclude COVID-19 project due to unsustainability. Post money...
317 Views